Cargando…

Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement

Spring and Summer 2020 are unique in that the challenges of care for those suffering from pollen allergy coincide with the COVID-19 pandemic. Several considerations are important to allow optimal care of allergic rhinitis (AR) and asthma and hence prevention of coronavirus spread through sneezing, r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scadding, Glenis K., Hellings, Peter W., Bachert, Claus, Bjermer, Leif, Diamant, Zuzana, Gevaert, Philippe, Kjeldsen, Anette, Kleine-Tebbe, Jorge, Klimek, Ludger, Muraro, Antonella, Roberts, Graham, Steinsvik, Andreas, Wagenmann, Martin, Wahn, Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	World Allergy Organization 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229977/ https://www.ncbi.nlm.nih.gov/pubmed/32426089 http://dx.doi.org/10.1016/j.waojou.2020.100124

Ejemplares similares

A EUFOREA comment on a lost comorbidity of asthma
por: Conti, Diego M., et al.
Publicado: (2023)

Allergic Rhinitis in Childhood and the New EUFOREA Algorithm
por: Scadding, Glenis Kathleen, et al.
Publicado: (2021)

EUFOREA Comment on a Misleading Allergic Rhinitis Report [Letter]
por: Scadding, Glenis K, et al.
Publicado: (2023)

White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA
por: De Prins, Louise, et al.
Publicado: (2022)

Corrigendum on: White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA
por: De Prins, Louise, et al.
Publicado: (2022)

EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care
por: Hellings, P. W., et al.
Publicado: (2023)

EUFOREA consensus on biologics for CRSwNP with or without asthma
por: Fokkens, Wytske J., et al.
Publicado: (2019)

Severe allergic reactions to the COVID-19 vaccine – statement and practical consequences
por: Kleine-Tebbe, Jörg, et al.
Publicado: (2021)

Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement
por: Hellings, P. W., et al.
Publicado: (2019)

Real‐life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA
por: Seys, Sven F., et al.
Publicado: (2020)

MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
por: Scadding, Glenis, et al.
Publicado: (2015)

A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
por: Hellings, Peter, et al.
Publicado: (2015)

Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
por: Scadding, Glenis, et al.
Publicado: (2013)

A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
por: Hellings, Peter, et al.
Publicado: (2013)

A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*
por: Bousquet, Jean, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion
por: Bachert, Claus, et al.
Publicado: (2013)

Patients Unmet Needs in Chronic Rhinosinusitis With Nasal Polyps Care: A Patient Advisory Board Statement of EUFOREA
por: Claeys, N., et al.
Publicado: (2021)

The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey
por: Price, David, et al.
Publicado: (2015)

Corrigendum: Patients Unmet Needs in Chronic Rhinosinusitis With Nasal Polyps Care: A Patient Advisory Board Statement of EUFOREA
por: Claeys, N., et al.
Publicado: (2021)

EUFOREA Comment on a Misleading Allergic Rhinitis Report [Response to Letter]
por: Fifer, Simon, et al.
Publicado: (2023)

A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress
por: Hellings, Peter W., et al.
Publicado: (2015)

Optimal management of allergic rhinitis
por: Scadding, Glenis K
Publicado: (2015)

A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.
por: Bachert, Claus, et al.
Publicado: (2015)

Cysteinyl–leukotriene and prostaglandin pathways in bronchial versus alveolar lavage in allergic asthmatics
por: van der Burg, Nicole, et al.
Publicado: (2022)

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated
por: Kariyawasam, Harsha H, et al.
Publicado: (2010)

Cost-effectiveness of SQ(®) HDM SLIT-tablet in addition to pharmacotherapy for the treatment of house dust mite allergic rhinitis in Germany
por: Green, William, et al.
Publicado: (2017)

Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma
por: Price, David, et al.
Publicado: (2020)

Clinical and daily respiratory care and clinical trials within the COVID-19 era
por: Diamant, Zuzana, et al.
Publicado: (2020)

P07 - Treatment load in the therapy management of allergic rhinitis: a UK retrospective database study
por: Carter, Victoria, et al.
Publicado: (2014)

Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients
por: Rieker-Schwienbacher, Juliane, et al.
Publicado: (2013)

Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care
por: De Jong, Hilda J.I., et al.
Publicado: (2020)

MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis
por: van Weissenbruch, Ranny, et al.
Publicado: (2020)

UK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational study
por: Price, David B, et al.
Publicado: (2016)

Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?
por: Van Broeck, Dorien, et al.
Publicado: (2023)

The launch of the European Clinical Respiratory Journal, the scientific forum of the Nordic Respiratory Academy
por: Bjermer, Leif, et al.
Publicado: (2014)

Diagnostic tools in Rhinology EAACI position paper
por: Scadding, Glenis, et al.
Publicado: (2011)

The importance of allergic disease in public health: an iCAALL statement
por: Sánchez-Borges, Mario, et al.
Publicado: (2018)

Correction to: Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper
por: Hox, Valerie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1s932jm83sg6ri9bdhmhg4ml7m